Perselin

Quick links to important sections

Perselin

Method of action: Progestogen

Treatment option: Miscarriage

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Perselin

Quick Facts

Property Description
Active ingredient Allylestrenol (also Allyloestrenol)
Form Oral tablet
Pharmacological class Progestogen (Progestin)
General purpose Progestational support
Origin Synthetic (Steroid derivative)

Identity, Classification, and Composition

Perselin is a single-component medication whose active ingredient is Allylestrenol, a substance classified within the synthetic progestogen drug class (ATC code G03DC01). Allylestrenol is a structurally modified steroid designed to functionally mimic the essential properties of the body's natural progesterone hormone. The drug is supplied specifically as an oral tablet and is clinically recognized for use where hormonal supplementation is required, defining its necessary oral route of administration for systemic effects. The pharmacological properties of Allylestrenol include its effect as a progestational agent, noting its clinical use in providing supportive therapy in specific reproductive contexts.

The Nature of Allylestrenol: Synthetic Origin and Functional Purity

Allylestrenol is defined as a synthetic compound, originating from laboratory synthesis; specifically, it is a derivative of 19-nortestosterone. This chemical modification grants the compound excellent oral activity, allowing it to be effectively absorbed when taken by mouth, which is a key differentiating factor from natural progesterone preparations. Pharmacological profiling characterizes Allylestrenol as a pure progestogen. This is a crucial distinction, as its structure is designed to exert its primary effects through the progesterone receptor while being largely devoid of androgenic or estrogenic activity, ensuring a targeted therapeutic action focused specifically on progestational support.

General Therapeutic Purpose and Mechanism Principle

The overarching therapeutic purpose of Perselin is to provide critical progestational support within the female reproductive system. It achieves this by functioning as a progesterone receptor agonist, the fundamental mechanism where it actively binds to and activates the body's progesterone receptors. This activation translates into two critical supportive effects: promoting endometrial stability (helping to maintain the lining of the uterus) and initiating relaxation of the uterine smooth muscle. These actions are central to its role in stabilizing the internal uterine environment, a typical use scenario being the provision of luteal phase support.

What side effects are possible with Perselin?

Possible Side Effects and Safety Information

The safety profile of Perselin (Allylestrenol) is categorized according to official regulatory standards and is structured around reported adverse reactions, high-level safety constraints, and population-specific considerations.

Adverse reactions classified as Common in regulatory documents often include gastrointestinal complaints, such as nausea and vomiting, alongside nervous system effects like headache and dizziness. General disorders such as breast tenderness, changes in body weight, and fatigue are also frequently reported.

System-Organ Classifications

Side effects are officially grouped by the organ systems they affect. Documented effects involve the Gastrointestinal System, Nervous System, Reproductive System and Breast, and Skin and Subcutaneous Tissue (e.g., acne, hirsutism). Gastrointestinal complaints are noted in regulatory information as being associated with long-term treatment.

Serious Adverse Reactions and Safety Constraints

The safety label includes critical restrictions for use. Perselin is contraindicated in patients with a history of thromboembolic events (blood clots), severe liver disease, and known hormone-dependent malignancies (such as certain breast or uterine cancers). Other absolute contraindications include undiagnosed vaginal bleeding and incomplete abortion.

Population-Specific Safety: Caution is advised when prescribing to patients with existing conditions like depression, renal impairment, or migraine headaches. The drug is not generally recommended for use in adolescents under 16 years of age, as safety data in this population is not fully established.

Overdose and Emergency Response

Overdose involving Perselin (Allylestrenol) is characterized by a low acute toxicity profile, meaning severe or life-threatening manifestations are not typically documented in official prescribing information following acute ingestion. Clinical signs associated with overexposure are generally limited to symptoms affecting the gastrointestinal and central nervous systems.

The documented manifestations observed in overdose include nausea, vomiting, and generalized drowsiness (somnolence). Acute oral toxicity is generally considered low, consistent with the expected profile of this progestogen class.

Immediate medical attention is officially required in any case of suspected overdosage. Consult a doctor or seek emergency medical treatment immediately following the ingestion of a quantity greater than the prescribed amount. This action is mandated for a full clinical assessment and observation, regardless of the apparent severity of initial symptoms. Continuous monitoring may be required to ensure the patient's clinical status stabilizes.

The official management of Perselin overdose is constrained, as no specific antidote is known or listed in regulatory documentation. Therefore, treatment is explicitly defined as symptomatic and supportive, aiming to manage the patient's clinical presentation until the documented manifestations resolve.

Therapeutic Uses of Perselin

The primary role of Perselin (Allylestrenol) is to provide progestational support within the female reproductive system in contexts where symptoms related to physiological strain are present. Its therapeutic relevance is applied across domains where additional symptomatic support is needed. For instance, Allylestrenol is applied to manage threatened pregnancies and in the context of premature labor.


Supporting Pregnancies Under Threat

Perselin is applied in clinical settings that involve acute or unstable symptom patterns, such as threatened miscarriage and threatened premature labor during gestation. This supportive symptom management is relevant for easing symptoms related to heightened physiological activity, like unexpected vaginal bleeding or pronounced pelvic cramping. The core benefit is providing support that helps ease the overall symptom burden, and may assist with maintaining functional stability. Common clinical indications include threatened abortion, habitual abortion, and threatened premature delivery.


Management of Recurrent Pregnancy Loss

This medication is commonly used across conditions presenting with acute episodes for women with a history of recurrent pregnancy loss, also known as habitual abortion. Perselin is applied in contexts where additional management of discomfort is required to support the uterine environment. This supportive role is used for managing symptoms that create noticeable physiological strain, which helps patients cope more steadily with symptom fluctuations and contributes to easing the overall symptom load.


Quick Fact: Relief for Heightened Physiological Activity Perselin supports the management of symptoms related to physical discomfort and symptoms linked to organ-specific functional stress during the critical phases of pregnancy.

Eligibility and Restrictions for Use

Who Can and Cannot Use Perselin?

The population eligibility for Perselin (Allylestrenol) is strictly defined by official regulatory labeling, outlining specific groups who are permitted, restricted, or prohibited from using the medicine.

Contraindicated Populations

Use is prohibited for individuals with certain high-risk conditions, classified as absolute contraindications in regulatory documents:

  • Known hypersensitivity to Allylestrenol or its components.
  • Patients with severe hepatic impairment or active severe liver disease.
  • Individuals with known or suspected hormone-dependent malignancies (e.g., breast or uterine cancer).
  • Patients with a history of thromboembolic disorders (blood clots) or cerebral apoplexy.
  • Cases of undiagnosed vaginal bleeding or incomplete abortion.

Age and Physiological Restrictions

Population Group Eligibility Status
Adult Women (Pregnant) Permitted (Primary indication)
Children & Adolescents Not Recommended (Safety not established)
Older Adults (Geriatric) Use Not Established
Lactating Women Not Recommended (Discontinuation advised)

Restricted Use (Caution Advised)

Official labeling requires caution and close supervision for patients with conditions such as renal dysfunction, diabetes, certain heart conditions, epilepsy, severe migraines, or history of depression.

What should I know about interactions with other medicines?

The interaction profile for Perselin (Allylestrenol) is primarily defined by the drug's metabolic pathway and the official constraints related to clearance function. The regulatory classification manages risks associated with changes in the drug's systemic exposure. All factual statements regarding interactions are based strictly on authoritative government regulatory documentation.

Interaction Profile Overview

Allylestrenol is cleared from the body through hepatic metabolism. This pathway makes the drug susceptible to interactions with other substances that either speed up or slow down liver enzyme activity, although a specific, universally citable list of interacting medicines is not published across all major government regulatory documents.

Interaction Constraint Official Regulatory Status
Disease-State Constraint Use is formally contraindicated in patients with severe hepatic (liver) impairment. This restriction prevents the risk of drug accumulation and heightened exposure due to impaired metabolic clearance.
Timing Rules No mandatory timing separation rules for administration with other medicines are specified in the official labeling.
Formal Drug-Drug Contraindications No specific drug-drug combinations are formally classified as contraindicated based only on an interaction risk in the accessible regulatory documents.

The overall structure of the regulatory profile is focused on managing the foundational risk related to metabolic function. This approach places the responsibility for safe administration on ensuring the patient possesses adequate hepatic clearance capacity, minimizing the risk of exposure-related changes from other medicines or underlying conditions.

Mechanism of Action

Perselin is a brand name for the synthetic progestogen allylestrenol. The compound functions primarily as an agonist of the progesterone receptor (PR), a member of the nuclear receptor superfamily.

Following administration, allylestrenol is considered a prodrug, which is metabolically converted to its active metabolite, 3-ketoallylestrenol (17alpha-allyl-19-nortestosterone), which possesses higher intrinsic affinity for the PR. The metabolite binds to the intracellular PR, inducing a conformational change that promotes receptor dimerization, nuclear translocation, and binding to specific progesterone response elements (PREs) in the genome's regulatory regions.

This molecular interaction modulates the transcription of target genes, leading to changes in the synthesis rates of specific messenger RNA and subsequent protein expression. At the system level, this transcriptional modulation results in antigonadotropic action, specifically in the male hypothalamic-pituitary-gonadal axis, manifesting as a significant suppression of luteinizing hormone (LH) release. The reduction in circulating LH subsequently leads to a substantial decrease in testicular testosterone and dihydrotestosterone (DHT) concentration in the systemic circulation.

Dosage and Administration Information

Perselin (Allylestrenol) is utilized as a single-component progestogen, administered through the oral route using the 5 mg tablet dosage form. Administration follows a distinct, biphasic pattern dependent on the clinical context and purpose of use.

For the management of acute symptomatic episodes, such as those associated with threatened abortion, the standard regimen involves taking 5 mg three times daily (totaling 15 mg per day). This acute, higher-frequency pattern is typically implemented as a short-term course, often for 5 to 7 days, and should be continued only until the active physical symptoms have fully subsided. In clinical scenarios involving imminent symptoms, the daily dose may be increased, with some regimens reaching up to 40 mg daily during the acute management phase.

In contrast, long-term administration for maintenance or prophylactic use, such as for habitual abortion, follows a lower-dose schedule, typically ranging from 5 mg to 10 mg daily. This supporting therapy commences upon the diagnosis of pregnancy and is continued for an extended period, minimally for one month beyond the critical stage of concern.

The administration process dictates that if a dose is missed, it should be taken when recalled; however, a double dose must never be taken to compensate for the omission. A key procedural instruction across all regimens is that therapy must conclude with a gradual dose reduction (tapering) rather than an abrupt stop. Furthermore, it is generally noted that Perselin is not recommended for administration in populations younger than 16 years of age.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Perselin (Allylestrenol)

Evidence for Use in Recurrent Pregnancy Loss

Research explored whether the agent was associated with recurrent pregnancy loss (habitual abortion) in women, utilizing Randomized Controlled Trials (RCTs) and retrospective comparative studies. Research examined key outcomes related to successful fetal development, specifically monitoring the live birth rate and the ongoing pregnancy rate during early gestation. Studies also monitored shifts in supportive hormone levels, which are outcomes related to physiological strain or stress.

Findings describe patterns observed in the studies related to how pregnancy outcomes evolved in the observed populations. Some comparative trials reported measurements of the live birth rate and ongoing pregnancy rates in groups receiving the progestational agent. The evidence landscape describes research where the broader class of progestogens was studied for conditions characterized by fluctuating or episodic manifestations.

Evidence for Use in Threatened Miscarriage

Research examined use for managing threatened miscarriage, utilizing retrospective/observational studies and trials comparing Perselin against other progestogens. Studies focused on episodes where symptoms become more noticeable, such as vaginal bleeding or pelvic cramping, which are outcomes related to physical discomfort. Comparison trials explored delivery outcomes and data show patterns related to those receiving other progestogens. Research highlights changes measured during the study period, with recorded differences in measures like the final gestational age at delivery being monitored in some cohorts.

Research Gaps and Areas of Scientific Uncertainty

Data are still emerging for some indications, and certainty remains low in certain areas. Key research limitation frames include the fact that many studies have modest sample sizes and the evidence quality varies across studies, often due to the reliance on older or retrospective designs rather than large, contemporary RCTs. Furthermore, long-term effects are not fully established, and research is ongoing to provide a clearer context. Results apply only to the populations studied, and data for certain groups remain insufficient.

Frequently Asked Questions (FAQ)

Common questions about Perselin (FAQ)

Q: Does Perselin cause weight gain or weight loss?

A: Official documentation states that 'changes in body weight' have been reported as a common adverse reaction for Perselin (Allylestrenol). This means some patients may experience a shift in their weight. However, the regulatory documentation lists this symptom without specifying the direction of the change (gain or loss).

Q: Can I drive or operate machinery while taking Perselin?

A: Perselin has been linked to central nervous system effects, such as dizziness and drowsiness, in official adverse reaction reports. Regulatory guidance advises caution regarding activities that require alertness, such as driving or operating heavy machinery, if side effects like dizziness or drowsiness are experienced.

Q: How quickly should I expect to feel the effects of Perselin?

A: Regulatory-cited literature and clinical summaries describe that the active ingredient in Perselin has a known onset of action. Official literature describes rapid absorption, contributing to its known onset. However, patient-facing documentation does not typically provide an exact timeframe (such as hours or days) for when symptomatic relief may occur.

Q: How long after stopping Perselin does it stay in my system?

A: Official product information notes that Perselin is cleared from the body primarily through liver metabolism. While this process is defined, the specific half-life or estimated time for the complete removal of the drug from the body is not usually included in the patient summary documentation.

Q: Does Perselin affect sleep?

A: While the official documentation for Perselin lists fatigue and other nervous system effects, specific sleep disturbances like insomnia or excessive sleepiness are generally not included among the commonly reported side effects. Any changes to sleep patterns are best reviewed with a healthcare provider.

Q: Does the effectiveness of Perselin decrease over time?

A: Regulatory-referenced research studies do not specifically address a decrease in the medication's effectiveness, also known as tolerance, during the approved term of use. Official information does note that data on the long-term effects of the drug are still being established.

Q: What is the main difference between Perselin and similar drugs used for the same purpose?

A: Official documents characterize Perselin (Allylestrenol) as a synthetic pure progestogen. This classification indicates that the compound’s primary action is through the progesterone receptor. Official information notes that it is largely devoid of the activity seen with other hormones, such as androgens or estrogens.

Q: Can Perselin be taken with common pain relievers like ibuprofen?

A: The official interaction profile for Perselin is mainly concerned with other medicines that significantly affect liver function. The drug label does not explicitly mention common over-the-counter pain relievers like ibuprofen or classify them as known interacting medicines.

Q: Is Perselin approved for long-term use?

A: The official administration instructions for Perselin describe a specific 'long-term administration for maintenance' regimen. This regimen, used for conditions like habitual abortion, is mandated to continue for an extended duration, typically for at least one month beyond the critical phase of concern.

Q: Can Perselin be taken with vitamins or supplements?

A: Official drug interaction information for Perselin does not specify any known interactions with common vitamins or general supplements. The focus of the interaction profile is typically on other prescription medications that may interfere with how the liver processes the drug.

Q: Is there a generic version of Perselin available?

A: Perselin is a brand name for the active ingredient Allylestrenol. In regions where the drug is available, the chemical name Allylestrenol may be used to identify generic versions of the medication.

Q: What are the main things I should avoid while using Perselin?

A: Official regulatory information describes conditions that prohibit the use of Perselin, classified as absolute contraindications. These include severe liver disease, a history of blood clots (thromboembolic events), or known hormone-dependent malignancies (such as specific cancers).

Q: Is Perselin commonly prescribed for conditions other than its main approved use?

A: The official regulatory label restricts information to only the approved uses for Perselin, which are for progestational support in specific reproductive contexts. Unapproved uses are not discussed in the product information.

Q: What kind of studies support the use of Perselin?

A: The evidence supporting the use of Perselin includes various study types, such as Randomized Controlled Trials (RCTs) and retrospective comparative studies. These studies have primarily monitored important outcomes, including the live birth rate, the ongoing pregnancy rate, and shifts in supportive hormone levels in the studied populations.

Q: Will Perselin affect my blood pressure?

A: The official label advises caution when Perselin is prescribed to patients with certain pre-existing heart conditions. Changes in blood pressure are not listed as a common adverse reaction in the official patient summary documents, though caution is advised for certain pre-existing heart conditions.

Q: Does Perselin interact with birth control pills?

A: Perselin and hormonal contraceptives are both steroid-based medicines that work on hormone receptors. Official regulatory documents indicate that concurrent use of Perselin with other hormonal contraceptives requires caution due to the potential for interactions.

Q: Is Perselin available in liquid form for people who have trouble swallowing?

A: The officially recognized and registered form of Perselin is the oral tablet. No other formulations, such as a liquid or chewable form, are specified in the regulatory documentation for this product.

Q: How common are serious side effects with Perselin?

A: The official safety documentation lists specific conditions, such as a history of blood clots or severe liver disease, as absolute contraindications. These restrictions imply that the corresponding serious adverse reactions, while considered rare, pose a high risk and require special caution.

Q: Can Perselin be split in half or crushed?

A: The administration instructions provided in the official regulatory guidance state that the tablets should be swallowed whole with water. No instruction for crushing, splitting, or otherwise manipulating the tablets is provided.

Q: Can Perselin affect fertility or cause issues during pregnancy planning?

A: Perselin is an approved medication indicated for use during pregnancy to help support the maintenance of the pregnancy. Official regulatory documentation does not report direct negative effects on fertility or pregnancy planning, aligning with its intended therapeutic use.

Q: What if I'm taking multiple medications; is Perselin safe?

A: The official label acknowledges that Perselin may interact with certain other medications. Managing the concurrent use of Perselin with multiple other medicines is a matter that should be discussed with a qualified healthcare provider to review and manage.

Q: Does the body build up a tolerance to Perselin?

A: Official documentation does not specifically mention the body building up a physical tolerance to Perselin. This effect is not described as a common characteristic of its approved progestational mechanism of action.

Q: Is there a certain time of day that is better for taking Perselin?

A: Official administration instructions recommend that Perselin be taken at approximately the same time each day to maintain consistent blood levels. The instructions do not mandate a specific morning or evening time.

Q: Can Perselin be taken on an empty stomach?

A: Administration instructions provided in the official regulatory documentation state that Perselin can be taken either with food or without food, as directed by the prescribing physician.

How should Perselin be stored and disposed of?

How to Store and Dispose of Perselin

Perselin (Allylestrenol) tablets must be stored and disposed of strictly according to the conditions specified on its official regulatory labeling to ensure product quality and public safety.


Storage Requirements

The medicine requires specific environmental control. It must be stored in a cool and dry place, typically meaning at controlled room temperature (e.g., below 25°C or 30°C). The official labeling mandates that the product must be protected from light and moisture and kept in its original container until use. As a universal safety rule, the product must be kept out of the sight and reach of children and stored locked up.

Disposal Instructions

Unused or expired Perselin tablets must be disposed of in accordance with local, regional, and national regulations for pharmaceutical waste. The product should not be discarded into household trash or wastewater systems unless the official labeling explicitly directs an alternative household disposal procedure.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Perselin found in:

A-Z Index: